Quantinno Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Quantinno Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-17,565	Closed	-$636K	–	614
2019 Q4	$636K	Buy	+17,565	New	+$539K	0.4%	47
2019 Q2	–	Sell	-23,245	Closed	-$614K	–	556
2019 Q1	$614K	Buy	23,245 +11,026	+90%	+$261K	0.39%	64
2018 Q4	$239K	Buy	+12,219	New	+$240K	0.19%	276

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Quantinno Capital Management's HZNP Position: Q1 2020 in Review

Quantinno Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2020, closing a stake of 17,565 shares — an estimated $636K sold.

Quantinno Capital Management first reported a position in HZNP in Q4 2018 and held it in 3 quarters. The position peaked at $636K in Q4 2019. 295 funds tracked by Wall St. Rank hold HZNP as of Q1 2020.

Quantinno Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2020 after selling out during the quarter.
Quantinno Capital Management sold 17,565 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2020, an estimated $636K.
Quantinno Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2018 and held it in 3 quarters.
Quantinno Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $636K in Q4 2019.
295 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2020.

Based on Quantinno Capital Management's 13F filing for Q1 2020, filed 15 May 2020.